Investment Thesis
UroGen shows strong product-market traction with 21.4% revenue growth and exceptional 91.9% gross margins, indicating genuine commercial acceptance. However, the company faces severe financial distress: negative stockholders' equity of -$124.3M, operating losses of -$20.3M, and negative free cash flow of -$45.4M represents unsustainable cash burn at ~2.4-year runway against $110M cash reserves. Without dramatic operational leverage or additional financing, the company faces solvency risk.
Strengths
- Strong revenue growth of 21.4% YoY demonstrates product commercialization traction
- Exceptional 91.9% gross margin indicates market acceptance and pricing power for core product
- Solid liquidity position with $110M cash and 4.69x current ratio provides near-term operational flexibility
Risks
- Negative stockholders' equity of -$124.3M indicates technical insolvency and balance sheet deterioration
- Operating cash flow burn of -$45.3M annually with only ~2.4 years of cash runway at current burn rate
- Operating margin of -39.8% and net margin of -46.3% show inability to achieve operational leverage despite revenue growth
- Total liabilities of $377.9M exceed total assets of $253.7M with $200M long-term debt burden
- Negative operating income of -$20.3M despite $51M revenue suggests severe cost structure misalignment
Key Metrics to Watch
- Operating cash flow trend - must trend positive to validate path to profitability
- Gross margin sustainability - monitor if margin compression occurs with scale
- Operating expense reduction - critical to achieve operating profitability before cash depletes
- Quarterly cash position and burn rate acceleration/deceleration
- Revenue growth maintenance - need continued strong growth to offset cost base
Financial Metrics
Revenue
51.0M
Net Income
-23.6M
EPS (Diluted)
$0.00
Free Cash Flow
-45.4M
Total Assets
253.7M
Cash
110.0M
Profitability Ratios
Gross Margin
91.9%
Operating Margin
-39.8%
Net Margin
-46.3%
ROE
N/A
ROA
-9.3%
FCF Margin
-89.0%
Balance Sheet & Liquidity
Current Ratio
4.69x
Quick Ratio
4.28x
Debt/Equity
N/A
Debt/Assets
149.0%
Interest Coverage
N/A
Long-term Debt
200.0M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-08T12:54:07.738383 |
Data as of: 2026-03-31 |
Powered by Claude AI